Previous 10 | Next 10 |
Redesigned platform offers ease-of-use, enhanced software engineering, and significant productivity gains for users Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods in...
2024-05-14 03:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-14 01:16:45 ET Summary Simulations Plus is benefiting from the growing use of computational tools in drug discovery, which would be boosted by the FDA Modernization Act 2.0. The biosimulation market is highly fragmented and underpenetrated, providing SLP with both organic ...
2024-05-04 09:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-04-04 12:19:09 ET More on Simulations Plus Simulations Plus, Inc. 2024 Q2 - Results - Earnings Call Presentation Simulations Plus, Inc. (SLP) Q2 2024 Earnings Call Transcript Simulations Plus: Questionable Whether It Will Benefit Or Be Hurt By Generative AI ...
Simulations Plus, Inc. (NASDAQ: SLP) is one of today's top gainers. The company's shares have moved 22.75% on the day to $47.21. Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial inte...
Predicting DILI risk supports informed decision-making regarding drug evaluations and approvals Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today anno...
2024-04-03 23:15:17 ET Simulations Plus, Inc. (SLP) Q2 2023 Results Earnings Conference Call April 4, 2024, 05:00 PM ET Company Participants Lisa Fortuna - Investor Relations, Financial Profiles Shawn O'Connor - Chief Executive Officer Will Frederick - Chief Fina...
2024-04-03 17:24:42 ET Gainers: Signature Bank ( OTC:SBNY ) +10% . MacroGenics ( MGNX ) +9% . Simulations Plus ( SLP ) +7% . Annexon ( ANNX ) +6% . 2seventy ( TSVT ) +5% . Losers: Cadiz ( CDZIP ) -11% . ...
Total revenue of $18.3 million and diluted earnings per share (EPS) of $0.20 Maintains full-year revenue guidance of $66 to $69 million (+10-15%) and EPS guidance of $0.66 to $0.68 Simulations Plus, Inc. (NASDAQ: SLP) (“Simulations Plus”), a leading provider of mod...
News, Short Squeeze, Breakout and More Instantly...
Objective to define best practices for the use of novel PBK modeling strategies to support animal-free safety assessment of new chemicals Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance an...
Total revenue of $18.5 million and diluted earnings per share (EPS) of $0.15 Maintains full-year revenue guidance of $69 to $72 million and updates EPS guidance Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulati...
2024-06-24 16:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...